The dopamine D2 receptor antagonist sulpiride causes long-lasting serotonin release

European Journal of Pharmacology

Volumn 363, Issue 1, 1998, Pages 29-34

  Nakazato, Taizo ^a   Horikawa, Hiroshi P M ^b   Akiyama, Akitane ^c  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

^c TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

5 HT (5 hydroxytryptamine, serotonin); Depression; Dopamine D2 receptor antagonist; Schizophrenia; Voltammetry, in vivo

Indexed keywords

DOPAMINE 2 RECEPTOR BLOCKING AGENT; SULPIRIDE; 5 HYDROXYINDOLEACETIC ACID; DOPAMINE RECEPTOR BLOCKING AGENT; FENCLONINE; SEROTONIN;

4 AMINOBUTYRIC ACID RELEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DEPRESSION; DRUG EFFECT; ELECTRODE; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; POTENTIOMETRY; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SEROTONIN RELEASE; SEROTONINERGIC SYSTEM; ANIMAL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMPEDANCE; METABOLISM; TIME; WISTAR RAT;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORPUS STRIATUM; DOPAMINE ANTAGONISTS; ELECTRIC IMPEDANCE; ELECTRODES, IMPLANTED; FENCLONINE; HYDROXYINDOLEACETIC ACID; MALE; RATS; RATS, WISTAR; SEROTONIN; SULPIRIDE; TIME FACTORS;

EID: 0032217061     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00796-1     Document Type: Article

References (37)

1. Akiyama A., Kato T., Ishii K., Yasuda E. In vitro measurement of dopamine concentration with carbon fiber electrode. Anal. Chem. 57:1985;1518-1522.
2. Ashcroft G., Crawford T.B.B., Eccleston D., Sharman D.F., MacDougall E.J., Stanton J.B., Binns J.K. 5-Hydroxyindole compounds in the cerebrospinal fluid of patients with psychiatric or neurological disease. Lancet. 2:1966;1049-1052.
3. Baldessarini R.J. Dopamine and the pathophysiology of dyskinesia induced by antipsychotic drugs. Annu. Rev. Neurosci. 3:1980;23-41.
4. Becquet D., Faudon M., Hery F. In vivo evidence for an inhibitory glutamatergic control of serotonin release in the cat caudate nucleus: involvement of GABA neurons. Brain Res. 519:1990;82-88.
5. Benloucif S., Galloway M.P. Facilitation of dopamine release in vivo by serotonin agonists: studied with microdialysis. Eur. J. Pharmacol. 200:1991;1-8.
6. Bodnoff S.R., Casotte B.S., Quirion R., Meaney M.J.A. Comparison of the effects of diazepam vs. several typical and atypical anti-depressant drugs in an animal model of anxiety. Psychopharmacology. 97:1989;277-279.
7. Boyer, W.F., 1992. Potential indications for the selective serotonin reuptake inhibitors. Int. Clin. Psychopharmacol. (Suppl. 6) 5-12.
8. Bürki H.R., Ruch W., Asper H. Effect of clozapine, thioridazine, perlapine and haloperidol on the metabolism of the biogenic amines in the brain of the rat. Pharmacologia. 41:1975;27-33.
9. Cervo L., Grignaschi G., Rossi C., Samanin R. Role of central serotonergic neurons in the effect of sertraline in rats in the forced swimming test. Eur. J. Pharmacol. 196:1991;217-222.
10. Cespuglio R., Faradji H., Ponchon J.L., Riou F., Buda M., Gonon F., Jouvet M. In vivo voltammetric measurement by differential pulse voltammetry of extracellular 5-hydroxyindoleacetic acid in the rat brain. J. Physiol. (London). 77:1981;327-332.
11. Coward D.W. General pharmacology of clozapine. Br. J. Psychiatry. 160:1992;5-11. (Suppl. 17).
12. Den Boer J.A., Westenberg H.G.M., Kamerbeek W.D.J., Verhoeven W.M.A., Kahn R.S. Effect of serotonin uptake inhibitors in anxiety disorder: a double-blind comparison of clomipramine and fluvoxamine. Int. Clin. Psychopharmacol. 2:1987;21-32.
13. Dewey S.L., Smith G.S., Logan J., Alexoff D., Ding Y.-S., King P., Pappas N., Brodie J.D., Ashby C.R. Jr. Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis. J. Neurosci. 15:1995;821-829.
14. Eastwood S.L., Story P., Burnet P.W.J., Health P., Harrison P.J. Differential changes in glutamate receptor subunit messenger RNAs in rat brain after haloperidol treatment. J. Psychopharmacol. 8:1994;196-203.
15. Euvrard C., Premont J., Oberlander C., Boissier J.R., Bockaert J. Dopamine sensitive adenylate cyclase involved in regulating the activity of striatal cholinergic neurons. Naunyn-Schmiedeberg's Arch. Pharmacol. 309:1979;241-245.
16. Ferrré S., Artigas F. Clozapine decreases serotonin extracellular levels in the nucleus accumbens by a dopamine receptor-independent mechanism. Neurosci. Lett. 187:1995;61-64.
17. Fitzgerald S.L., Deutch A.Y., Gasic G., Heineman E.J., Nestler E.J. Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs. J. Neurosci. 15:1995;2453-2461.
18. Fuller R.W. Uptake inhibitor increase extracellular serotonin concentration measured by brain microdialysis. Life Sci. 55:1994;163-167.
19. 3H ]-aminobutyric acid in the rat neostriatum: I. Characterization and topographical heterogeneity of the effects of dopaminergic and cholinergic agents Neuroscience. 19:1986;1101-1108.
20. 3H ]-aminobutyric acid in the rat neostriatum: II. Opposing effects of D1 and D2 dopamine receptor stimulation in the dorsal caudate putamen Neuroscience. 19:1986;1109-1117.
21. Healy D.J., Woodruff J.H.M. Clozapine and haloperidol differentially affect AMPA and kainate receptor subunit mRNA levels in rat cortex and striatum. Mol. Brain Res. 47:1997;331-338.
22. Horikawa H.P.M., Nakazato T., Hikosaka O. Duration of catalepsy correlates with increased intrastriatal sulpiride. Eur. J. Pharmacol. 326:1997;15-23.
23. Imperato A., Di Chiara G. Effect of locally applied D-1 and D-2 receptor agonists and antagonists studied with brain dialysis. Eur. J. Pharmacol. 156:1988;385-393.
24. Kane J., Honigfeld G., Singer J., Meltzer H.Y. Clozapine for the treatment-resistant schizophrenia. Arch. Gen. Psychiatry. 45:1988;789-796.
25. Kennett G.A., Joseph M.H. Does in vivo voltammetry in the hippocampus measure 5-HT release? Brain Res. 236:1982;305-316.
26. Klawans H.L., Rubovits R. An experimental model of tardive dyskinesia. J. Neural. Trans. 33:1972;235-246.
27. Lehmann J., Langer S.Z. The striatal cholinergic interneurons: synaptic target of dopaminergic terminals? Neuroscience. 10:1983;1105-1120.
28. Martin P., Soubrie P., Puech A.J. Reversal of helpless behavior by serotonin uptake blockers in rats. Psychopharmacology. 101:1990;403-407.
29. Meltzer, H.Y., Bastani, B., Kwon, K.Y., Ramirez, L., Burnett, S., Sharp, J., 1989. A prospective study of clozapine in treatment resistant schizophrenic patients: I. Preliminary report. Psychopharmacol. (Suppl. 99) S68-72.
30. Nakazato T., Akiyama A. In vivo voltammetric study of 6-hydroxydopamine-induced neuronal degradation. J. Neurochem. 51:1988;1007-1013.
31. Nakazato T., Akiyama A. Immediate and long-term effects of 5,7- dihydroxytryptamine on rat striatal neurons measured using in vivo voltammetry. Neurosci. Res. 23:1998;1-6.
32. Rivot J.P., Pointis D., Besson J.M. Morphine increases 5-HT metabolism in the nucleus raphe magnus: an in vivo study in freely moving rats using 5-hydroxyindole electrochemical detection. Brain Res. 446:1988;333-342.
33. Sayers A.C., Bürki H.R., Ruch W., Asper H. Neuroleptic-induced hypersensitivity of striatal dopamine receptors in the rat as a model of tardive dyskinesia. Effect of clozapine, haloperidol, loxapine and chlorpromazine. Psychopharmacologia. 41:1975;97-104.
34. Stoof J.C., Kebabian J.W. Independent in vitro regulation by the D2 dopamine receptor of dopamine-stimulated efflux of cyclic AMP and K+-stimulated release of acetylcholine from rat neostriatum. Brain Res. 250:1982;263-270.
35. Van der Heyden J.A.M., Venema K., Korf J. In vivo release of endogenous gamma-aminobutyric acid from rat striatum: inhibition by dopamine. J. Neurochem. 34:1980;1338-1341.
36. Wong P.T.-H., Fang H., Teo W.L. Interaction of the dopaminergic and serotonergic systems in the rat striatum: effects of selective antagonists and uptake inhibitors. Neurosci. Res. 23:1995;115-119.
37. Zetterström T., Sharp T., Ungerstedt U. Effect of neuroleptic drugs on striatal dopamine release and metabolism in awake rat studied by intracerebral dialysis. Eur. J. Pharmacol. 106:1984;27-37.